Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

By Eileen M. Foy, Kui Li, Chunfu Wang, R. Sumpter, M. Ikeda, S. Lemon, M. Gale. Science, 2003

888 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5146e4affbbfb9cc3a17901a0aa7b9696923253e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Shizuo Akira
2. R. Medzhitov
3. Daniel B. Stetson
4. L. Guidotti
5. Kui Li
6. F. Chisari
7. Eileen M. Foy
8. A. García‐Sastre

In Hepatology

1. Shizuo Akira
2. Eileen M. Foy
3. R. Medzhitov
4. Peter Simmonds
5. M. Gale
6. L. Guidotti
7. B. Rehermann
8. M. Nascimbeni

In Rheumatology

1. Shizuo Akira
2. Daniel B. Stetson
3. R. Medzhitov

Citations in the corpus

• Evasion of intracellular host defence by hepatitis C virus (2005, background): “The helicase activity of NS3 is dispensable for the control of IRF-3 activation, but NS3/4A protease activity is required for this regulatio”
• Type I interferons in host defense. (2006, positive): “Additionally, viruses are known to target both type I IFN receptor signaling as well as the signaling machinery that links cytosolic nucleic acid recognition to activation of type I IFNs (Foy et al., 2003; Garcia-Sastre and Biron, 2006).”
• Immunology of hepatitis B virus and hepatitis C virus infection (2005, background): “First, the HCV serine protease NS3–NS4A blocks IRF3-mediated induction of type I IFN in vitro”
• Immunobiology and pathogenesis of viral hepatitis. (2006, background): “However, as IFN induced genes are strongly upregulated during HCV infection, the negative impact of NS3 on IRF-3 activation in the liver would appear to be minimal.”
• Genetic diversity and evolution of hepatitis C virus--15 years on. (2004, background): “It has also recently been shown that the HCV NS3/4A protease blocks the phosphorylation and signalling function of the antiviral IFN regulatory factor 3 (Foy et al., 2003).”
• Distinct RIG-I and MDA5 Signaling by RNA Viruses in Innate Immunity (2007, background): “Renilla-luc and IFN-β-luc constructs have been described (9); siRNA to RIG-I (Genome”
• Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I (2005, methodology): “The IRF3 response contributes to control of HCV RNA replication (7).”
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus (2003, background): “It has been reported recently that HCV protease inhibition may lead to a restoration of the cellular antiviral response mediated by IFN regulatory factor 3 (ref”